-
1.发明授权
公开(公告)号：US5861159A
公开(公告)日：1999-01-19
申请号：US586143
申请日：1996-01-16
申请人： Drew Pardoll , Rosa Azhari , Kam W. Leong , Paul Golumbek , Elizabeth Jaffee , Hyam Levitsky , Audrey Lazenby
发明人： Drew Pardoll , Rosa Azhari , Kam W. Leong , Paul Golumbek , Elizabeth Jaffee , Hyam Levitsky , Audrey Lazenby
IPC分类号： A61K47/44 , A61K9/16 , A61K38/00 , A61K38/19 , A61K38/21 , A61K39/00 , A61K39/12 , A61K39/39 , A61K45/00 , A61K51/00 , A61P35/00 , A61P37/04 , A61P43/00 , A61K48/00 , A61K45/05
CPC分类号： C12N15/86 , A61K38/193 , A61K38/217 , A61K39/0011 , A61K39/39 , A61K9/1652 , A61K9/1658 , A61K2039/5152 , A61K2039/55522 , C12N2740/13043 , Y10S977/906 , Y10S977/907 , Y10S977/911 , Y10S977/912 , Y10S977/915 , Y10S977/92
摘要： A method of stimulating a systemic immune response to a tumor cell or antigen associated with a pathogen by administering a mixture of a controlled release vehicle containing an immunopotentiating agent and antigen is described. The method of the invention provides sustained release of therapeutic compounds to allow a host immune system to ameliorate local as well as metastatic tumors in the host. The immunopotentiating agent is typically a cytokine such as tumor necrosis factor, GM-CSF, interleukin or interferon, for example.
摘要翻译： 描述了通过施用含有免疫增强剂和抗原的控释载体的混合物来刺激与病原体相关的肿瘤细胞或抗原的全身免疫应答的方法。 本发明的方法提供治疗化合物的持续释放，以允许宿主免疫系统改善宿主中的局部和转移性肿瘤。 免疫增强剂通常是细胞因子，例如肿瘤坏死因子，GM-CSF，白介素或干扰素。
-
2.发明授权公开(公告)号：US06193970B1
公开(公告)日：2001-02-27
申请号：US09152918
申请日：1998-09-14
申请人： Drew Pardoll , Rosa Azhari , Kam W. Leong , Paul K Golumbe , Elizabeth Jaffee , Hyam Levitsky , Audrey Lazenby
发明人： Drew Pardoll , Rosa Azhari , Kam W. Leong , Paul K Golumbe , Elizabeth Jaffee , Hyam Levitsky , Audrey Lazenby
IPC分类号： A61K4700
CPC分类号： C12N15/86 , A61K9/1652 , A61K9/1658 , A61K38/193 , A61K38/217 , A61K39/0011 , A61K39/39 , A61K2039/5152 , A61K2039/55522 , C12N2740/13043 , Y10S977/906 , Y10S977/907 , Y10S977/911 , Y10S977/912 , Y10S977/915 , Y10S977/92
摘要： A method of stimulating a systemic immune response to a tumor cell or antigen associated with a pathogen by administering a mixture of a controlled release vehicle containing an immunopotentiating agent and antigen is described.
摘要翻译： 描述了通过施用含有免疫增强剂和抗原的控释载体的混合物来刺激与病原体相关的肿瘤细胞或抗原的全身免疫应答的方法。
-
公开(公告)号：US20090165152A1
公开(公告)日：2009-06-25
申请号：US12210604
申请日：2008-09-15
申请人： Elizabeth Jaffee , Tzyy-Choou Wu , Chien-Fu Hung , Ralph Hruban
发明人： Elizabeth Jaffee , Tzyy-Choou Wu , Chien-Fu Hung , Ralph Hruban
IPC分类号： A61B10/00 , C12Q1/68 , C12N5/10 , A01K67/027
CPC分类号： A61K39/0011 , A61K2039/523 , A61K2039/53 , A61K2039/57 , A61K2039/6031 , Y02A50/484
摘要： Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
摘要翻译： 间皮素可用作免疫治疗靶标。 它诱导细胞溶解性T细胞反应。 确定诱导这种反应的间皮素的部分。 疫苗可以是多核苷酸或基于多肽的。 提高溶细胞T细胞应答的载体包括细菌和病毒。 用于测试疫苗和其他抗肿瘤治疗剂和预防剂的小鼠模型包括强表达间皮素的转化的腹膜细胞系。
-
公开(公告)号：US08137908B2
公开(公告)日：2012-03-20
申请号：US12210604
申请日：2008-09-15
申请人： Elizabeth Jaffee , Ralph Hruban
发明人： Elizabeth Jaffee , Ralph Hruban
CPC分类号： A61K39/0011 , A61K2039/523 , A61K2039/53 , A61K2039/57 , A61K2039/6031 , Y02A50/484
摘要： Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
摘要翻译： 间皮素可用作免疫治疗靶标。 它诱导细胞溶解性T细胞反应。 确定诱导这种反应的间皮素的部分。 疫苗可以是多核苷酸或基于多肽的。 提高溶细胞T细胞应答的载体包括细菌和病毒。 用于测试疫苗和其他抗肿瘤治疗剂和预防剂的小鼠模型包括强表达间皮素的转化的腹膜细胞系。
-
公开(公告)号：US09200036B2
公开(公告)日：2015-12-01
申请号：US13293357
申请日：2011-11-10
申请人： Elizabeth Jaffee , Ralph Hruban
发明人： Elizabeth Jaffee , Ralph Hruban
CPC分类号： A61K39/0208 , A01K2267/0331 , A61K39/0011 , A61K2039/505 , A61K2039/5154 , A61K2039/52 , A61K2039/522 , A61K2039/523 , A61K2039/53 , A61K2039/55511 , A61K2039/55522 , A61K2039/57 , A61K2039/6031 , C07K7/06 , C07K14/4748 , C07K16/30 , C12N15/74 , C12N15/8509 , C12N2710/16522 , C12N2740/13043 , Y02A50/484
摘要： Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
摘要翻译： 间皮素可用作免疫治疗靶标。 它诱导细胞溶解性T细胞反应。 确定诱导这种反应的间皮素的部分。 疫苗可以是多核苷酸或基于多肽的。 提高溶细胞T细胞应答的载体包括细菌和病毒。 用于测试疫苗和其他抗肿瘤治疗剂和预防剂的小鼠模型包括强表达间皮素的转化的腹膜细胞系。
-
公开(公告)号：US20090110702A1
公开(公告)日：2009-04-30
申请号：US12049763
申请日：2008-03-17
申请人： T.C. WU , Chien-Fu Hung , Elizabeth Jaffee , Ralph Hruban
发明人： T.C. WU , Chien-Fu Hung , Elizabeth Jaffee , Ralph Hruban
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A01K2267/0331 , A61K2039/505 , A61K2039/522 , A61K2039/523 , A61K2039/53 , A61K2039/55522 , A61K2039/57 , A61K2039/6031 , C07K16/30 , C12N15/8509 , C12N2710/16522 , C12N2740/13043
摘要： Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
摘要翻译： 间皮素可用作免疫治疗靶标。 它诱导细胞溶解性T细胞反应。 确定诱导这种反应的间皮素的部分。 疫苗可以是多核苷酸或基于多肽的。 提高溶细胞T细胞应答的载体包括细菌和病毒。 用于测试疫苗和其他抗肿瘤治疗剂和预防剂的小鼠模型包括强表达间皮素的转化的腹膜细胞系。
-
7.发明申请Method for inhibiting cancer development by fatty acid synthase inhibitors 审中-公开通过脂肪酸合酶抑制剂抑制癌症发展的方法公开(公告)号：US20070142456A1
公开(公告)日：2007-06-21
申请号：US10533311
申请日：2003-10-31
IPC分类号： A61K31/381 , A61K31/365
CPC分类号： A61K31/365 , A61K31/00 , A61K31/34 , A61K31/381
摘要： A method for inhibiting or preventing cancer development by the administration of fatty acid synthase (FAS) inhibitors. In particular, the present invention prohibits or delays the development of invasive cancer from pre-malignant (non-invasive) lesions that express FAS. Compositions containing FAS inhibitors also are provided, as well as methods for administering the FAS inhibitors and compositions to patients in need thereof.
摘要翻译： 通过施用脂肪酸合成酶（FAS）抑制剂抑制或预防癌症发展的方法。 特别地，本发明禁止或延迟侵入性癌症从表达FAS的恶性前（非侵入性）损伤的发展。 还提供了含有FAS抑制剂的组合物，以及用于将FAS抑制剂和组合物给予有此需要的患者的方法。
-
公开(公告)号：US20070059315A1
公开(公告)日：2007-03-15
申请号：US11489762
申请日：2006-07-19
申请人： Elizabeth Jaffee
发明人： Elizabeth Jaffee
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： A61K39/0011 , A61K38/1774 , A61K2039/53 , G01N33/505 , Y02A50/484
摘要： This invention relates to the identification of prostate stem cell antigen (PSCA) as a target of clinically relevant antitumor immune responses. The invention provides vaccines comprising PSCA, or fragments thereof, which are useful in inducing antitumor immune responses, including PSCA specific CD8+ T cell responses. Methods of using the compositions to treat cancer are also provided. The invention further provides methods of identifying compounds useful in antitumor vaccines and methods of assessing the responses of patients to cancer immunotherapy.
摘要翻译： 本发明涉及鉴定前列腺干细胞抗原（PSCA）作为临床相关抗肿瘤免疫反应的靶标。 本发明提供了包含PSCA或其片段的疫苗，其可用于诱导抗肿瘤免疫应答，包括PSCA特异性CD8 + T细胞应答。 还提供了使用该组合物治疗癌症的方法。 本发明还提供鉴定用于抗肿瘤疫苗的化合物的方法和评价患者对癌症免疫治疗的反应的方法。
-
公开(公告)号：US20050175625A1
公开(公告)日：2005-08-11
申请号：US10618088
申请日：2003-07-14
申请人： Elizabeth Jaffee , Tzyy-Choou Wu , Chien-Fu Hung , Ralph Hruban
发明人： Elizabeth Jaffee , Tzyy-Choou Wu , Chien-Fu Hung , Ralph Hruban
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K2039/523 , A61K2039/53 , A61K2039/57 , A61K2039/6031 , Y02A50/484
摘要： Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
摘要翻译： 间皮素可用作免疫治疗靶标。 它诱导细胞溶解性T细胞反应。 确定诱导这种反应的间皮素的部分。 疫苗可以是多核苷酸或基于多肽的。 提高溶细胞T细胞应答的载体包括细菌和病毒。 用于测试疫苗和其他抗肿瘤治疗剂和预防剂的小鼠模型包括强表达间皮素的转化的腹膜细胞系。
-
10.发明授权Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same 失效表达共享的免疫显性黑素瘤抗原的黑素瘤细胞系及其使用方法公开(公告)号：US06187306B1
公开(公告)日：2001-02-13
申请号：US08906029
申请日：1997-08-05
IPC分类号： A61K4800
CPC分类号： A61K39/0011 , A61K39/00 , A61K48/00 , A61K2039/5152 , A61K2039/5156 , A61K2039/55522
摘要： The invention pertains to a method of treating or protecting against melanoma that comprises (a) obtaining a melanoma cell line that expresses one or more shared immunodominant melanoma antigens, (b) modifying the melanoma cell line to render it capable of producing an increased level of a cytokine relative to the unmodified cell line, and (c) administering the melanoma cell line to a mammalian host that has melanoma or is at risk for developing melanoma. Preferably the melanoma cell line is allogeneic and is not MHC-matched to the host.
摘要翻译： 本发明涉及治疗或保护黑色素瘤的方法，其包括（a）获得表达一种或多种共同免疫显性黑素瘤抗原的黑素瘤细胞系，（b）修饰黑素瘤细胞系以使其能够产生增加的水平 相对于未修饰的细胞系的细胞因子，和（c）将黑素瘤细胞系施用于具有黑素瘤或具有发展黑素瘤风险的哺乳动物宿主。 优选地，黑素瘤细胞系是同种异体的，并且不与宿主MHC匹配。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.038 秒)
